Key clinical point: Discontinuing or reducing peanut OIT to 300 mg daily increased the potential of regaining an allergic reaction.
Major finding: At week 156, after a year of avoiding peanut, 37% of patients reduced to 300 mg of peanut OIT passed an allergy challenge, compared with 13% of those who totally discontinued OIT and 4% of a placebo group.
Study details: The data come from a randomized, phase 2 study of 120 individuals aged 7-55 years with peanut allergies.
Disclosures: The National Institutes of Health supported the study. The researchers had no financial conflicts to disclose.
Chinthrajah RS et al. Lancet. 2019 Sep 12. doi: 10.1016/S0140-6736(19)31793-3.